title: Should atenolol still be recommended as first-line therapy for primary hypertension?
authors.affiliation: Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece. astkar@med.auth.gr
authors.forename: Asterios
authors.initials: A
authors.lastname: Karagiannis
authors.forename: Vasilios G
authors.initials: VG
authors.lastname: Athyros
authors.forename: Athanasios
authors.initials: A
authors.lastname: Papageorgiou
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Tziomalos
authors.forename: Moses
authors.initials: M
authors.lastname: Elisaf
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D001262:Atenolol / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate
chemical_list: D000319:Adrenergic beta-Antagonists; D001262:Atenolol